Physician profile
Marion A Trybula
NPI 1396722328
$6,030.95
in general payments reported to CMS, 2019-2025
43 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,295 · 2020: $3,494 · 2021: $145 · 2023: $97.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $97.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $97.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $2,334.11 | 2019-2020 | |
| Genentech USA, INC. | $328.35 | 2019-2021 | |
| Amgen INC. | $226.23 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $224.39 | 2019-2020 | |
| Janssen Biotech, INC. | $223.06 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $202.49 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $200.51 | 2019 | |
| Janssen Pharmaceuticals, INC | $183.95 | 2019-2020 | |
| Pfizer INC. | $181.28 | 2019-2020 | |
| Astellas Pharma US INC | $167.16 | 2019-2020 | |
| Abbvie INC. | $157.22 | 2019-2023 | Venclexta |
| E.R. Squibb & Sons, L.L.C. | $154.81 | 2019-2021 | |
| Exelixis INC. | $141.20 | 2020 | |
| Puma Biotechnology, INC. | $123.12 | 2019 | |
| Celgene Corporation | $113.32 | 2019-2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marion Trybula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.